Literature DB >> 20468067

LINGO1 is not associated with Parkinson's disease in German patients.

Stephan Klebe1, Sandra Thier, Delia Lorenz, Michael Nothnagel, Stefan Schreiber, Christine Klein, Johann Hagenah, Meike Kasten, Daniela Berg, Karin Srulijes, Thomas Gasser, Günther Deuschl, Gregor Kuhlenbäumer.   

Abstract

Essential tremor (ET) and Parkinson's disease (PD) are the most common movement disorders and show clinical, genetic, and pathophysiological overlap. Single-nucleotide polymorphisms (SNPs) in the leucine-rich repeat (LRR) and immunoglobulin (Ig) domain-containing, Nogo receptor-interacting protein gene (LINGO1) are associated with ET. LINGO1 is overexpressed in the substantia nigra (SN) of PD patients and inhibition of LINGO1 confers neuroprotection in a rodent model of PD. In this study we test the hypothesis whether SNPs in the LINGO1 gene that are associated with ET are also associated with PD. Three large German case-control samples from Kiel, Lübeck, and Tübingen (total: 1,798 cases and 1,482 controls) were genotyped for the three LINGO1 SNPs associated with ET. Association was assessed using allele- and genotype-based tests in each of the three samples separately, in the combined sample, and in subsets of patients with early-onset PD (<50 years) and of patients with a positive family history of PD. Neither of the three samples alone nor the combined sample showed evidence for association between LINGO1 SNPs and PD. The allele-based test showed a trend toward nominal association for all three SNPs in the Kiel sample. The subsets with early-onset PD or a positive family history did also not reveal evidence for association. SNPs in the LINGO1 gene associated with ET could not be shown to be associated with PD in our study population, despite a postulated overlap between both diseases. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20468067     DOI: 10.1002/ajmg.b.31085

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  5 in total

1.  Genetic variants of α-synuclein are not associated with essential tremor.

Authors:  Owen A Ross; Karen N Conneely; Tao Wang; Carles Vilarino-Guell; Alexandra I Soto-Ortolaza; Alex Rajput; Zbigniew K Wszolek; Ryan J Uitti; Elan D Louis; Lorraine N Clark; Matthew J Farrer; Claudia M Testa
Journal:  Mov Disord       Date:  2011-10-24       Impact factor: 10.338

2.  Analysis and meta-analysis of five polymorphisms of the LINGO1 and LINGO2 genes in Parkinson's disease and multiple system atrophy in a Chinese population.

Authors:  YongPing Chen; Bei Cao; Jing Yang; QianQian Wei; Ru Wei Ou; Bi Zhao; Wei Song; XiaoYan Guo; HuiFang Shang
Journal:  J Neurol       Date:  2015-08-08       Impact factor: 4.849

3.  No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease.

Authors:  Silke Appenzeller; Claudia Schulte; Sandra Thier; Franziska Hopfner; Manuela Pendziwiat; Frank Papengut; Christine Klein; Johann Hagenah; Meike Kasten; Karin Srulijes; Daniela Berg; Thomas Gasser; Andrew Singleton; Günther Deuschl; Gregor Kuhlenbäumer
Journal:  Mov Disord       Date:  2013-02-06       Impact factor: 10.338

4.  SLC1A2 rs3794087 does not associate with essential tremor.

Authors:  Jay P Ross; Sruti Rayaprolu; Cecily Q Bernales; Alexandra I Soto-Ortolaza; Jay van Gerpen; Ryan J Uitti; Zbigniew K Wszolek; Alex Rajput; Ali H Rajput; Michele L Rajput; Owen A Ross; Carles Vilariño-Güell
Journal:  Neurobiol Aging       Date:  2013-10-16       Impact factor: 4.673

5.  LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis.

Authors:  Elena García-Martín; Oswaldo Lorenzo-Betancor; Carmen Martínez; Pau Pastor; Julián Benito-León; Jorge Millán-Pascual; Patricia Calleja; María Díaz-Sánchez; Diana Pisa; Laura Turpín-Fenoll; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecillas; Elena Lorenzo; José Francisco Plaza-Nieto; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  BMC Neurol       Date:  2013-04-10       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.